Initiation of Two Phase II Studies with Ipsen’s Proprietary BIM 23A760 First-in-Class Chimeric Compound in the Treatment of Acromegaly and Carcinoid Syndrome Due to Neuroendocrine Tumors

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.